TBPH — Theravance Biopharma Income Statement
0.000.00%
Last trade - 00:00- $841.91m
- $559.35m
- $107.46m
Annual income statement for Theravance Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 55.3 | 51.3 | 57.4 | 64.4 | 107 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 313 | 146 | 113 | 111 | 61.1 |
| Operating Profit | -258 | -95 | -56 | -46.9 | 46.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -265 | -92.8 | -49.3 | -44.6 | 129 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -265 | -92.8 | -55.2 | -56.4 | 106 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -199 | 872 | -55.2 | -56.4 | 106 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -199 | 872 | -55.2 | -56.4 | 106 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.63 | -1.12 | -0.966 | -1.09 | 1.26 |